ABMD ABIOMED, Inc.

Price (delayed)

$265.07

Market cap

$11.94B

P/E Ratio

75.52

Dividend/share

N/A

EPS

$3.51

Enterprise value

$11.73B

Sector: Healthcare
Industry: Medical Devices
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.

Highlights

Abiomed's equity has increased by 10% YoY and by 3.4% from the previous quarter
ABMD's quick ratio is down by 19% year-on-year but it is up by 16% since the previous quarter
ABMD's P/E is 79% above its last 4 quarters average of 42.2
ABMD's EPS is down by 39% year-on-year and by 22% since the previous quarter

Key stats

What are the main financial stats of ABMD
Market
Shares outstanding
45.05M
Market cap
$11.94B
Enterprise value
$11.73B
Valuations
Price to earnings (P/E)
75.52
Price to book (P/B)
10.82
Price to sales (P/S)
14.95
EV/EBIT
54.6
EV/EBITDA
49.62
EV/Sales
14.69
Earnings
Revenue
$798.07M
EBIT
$214.76M
EBITDA
$236.31M
Free cash flow
$240.25M
Per share
EPS
$3.51
Free cash flow per share
$5.34
Book value per share
$24.51
Revenue per share
$17.73
TBVPS
$26.05
Balance sheet
Total assets
$1.25B
Total liabilities
$147.66M
Debt
$0
Equity
$1.1B
Working capital
$509.31M
Liquidity
Debt to equity
0
Current ratio
5.61
Quick ratio
4.62
Net debt/EBITDA
-0.91
Margins
EBITDA margin
29.6%
Gross margin
81.2%
Net margin
19.9%
Operating margin
27.9%
Efficiency
Return on assets
13.3%
Return on equity
15.1%
Return on invested capital
24.8%
Return on capital employed
18.9%
Return on sales
26.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABMD stock price

How has the Abiomed stock price performed over time

Financial performance

How have Abiomed's revenue and profit performed over time
Revenue
$798.07M
Gross profit
$647.85M
Operating income
$222.56M
Net income
$158.67M
Gross margin
81.2%
Net margin
19.9%
ABMD's net margin is down by 39% year-on-year and by 17% since the previous quarter
The net income has contracted by 39% YoY and by 22% from the previous quarter
The company's operating income fell by 11% QoQ and by 7% YoY
Abiomed's operating margin has decreased by 7% YoY and by 6% QoQ

Growth

What is Abiomed's growth rate over time

Valuation

What is Abiomed stock price valuation
P/E
75.52
P/B
10.82
P/S
14.95
EV/EBIT
54.6
EV/EBITDA
49.62
EV/Sales
14.69
ABMD's P/E is 79% above its last 4 quarters average of 42.2
ABMD's EPS is down by 39% year-on-year and by 22% since the previous quarter
ABMD's P/B is 37% above its last 4 quarters average of 7.9 but 18% below its 5-year quarterly average of 13.2
Abiomed's equity has increased by 10% YoY and by 3.4% from the previous quarter
The price to sales (P/S) is 48% higher than the last 4 quarters average of 10.1
The company's revenue fell by 5% QoQ

Efficiency

How efficient is Abiomed business performance
Abiomed's ROA has decreased by 48% YoY and by 24% from the previous quarter
ABMD's return on equity is down by 48% year-on-year and by 24% since the previous quarter
The ROIC has contracted by 39% YoY and by 15% from the previous quarter
ABMD's return on sales is down by 33% year-on-year and by 12% since the previous quarter

Dividends

What is ABMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABMD.

Financial health

How did Abiomed financials performed over time
Abiomed's total liabilities has increased by 21% YoY but it has decreased by 2.2% QoQ
ABMD's quick ratio is down by 19% year-on-year but it is up by 16% since the previous quarter
ABMD's debt is 100% smaller than its equity
Abiomed's equity has increased by 10% YoY and by 3.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.